So, again, I just can't predict where this all goes, but I'm concerned. I don't know what else I can really say,” Johnson said ...

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes two weeks after J&J ...

Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the stock has risen by around just 3%. This is not the type of investment ...

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment isn’t ...

AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are ...

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

"Treatment-resistant depression can be very complicated ... Ph.D., Global Therapeutic Area Head, Neuroscience, Johnson & ...

depression. Back in 2018, Johnson opened up about his struggles with mental health, showing fans that even the “big guy” isn’t invincible. It all started with a raw confession. Johnson ...